Game-Changing Tumor Freezing Technology Has The Potential To Offer Women First-Ever Minimally Invasive Alternative To Breast Lumpectomy Surgery
–News Direct–
By Meg Flippin, Benzinga
IceCure Medical Ltd. (NASDAQ: ICCM), which is set to submit results from the largest cryoablation study of its kind to the FDA, may set a new standard of care for early-stage breast cancer in women who elect not to have surgery. This could be a game-changer for the medical community and IceCure alike.
When it comes to the early onset of breast cancer, the typical treatment protocol is for women to undergo a lumpectomy followed by chemotherapy, hormone or radiation therapy. The lumpectomy involves removing the tumor and some healthy tissue around it surgically in a hospital operating room. It requires heavy sedation, is often painful and has a long recovery time.
While tens of thousands of lumpectomies are performed annually in the U.S., it is not...